Bill Taranto

And we're going to continue investing that in the future as we look forward.

Yeah, that's a great question.

You know, an AI is not necessarily anything new.

If you look at preventive surgery, it was using, you know, early sort of technology of AI to identify a fib and stroke.

So it's been around.

But we kind of think of, you know, agendic AI for biopharma operations is probably the most underestimated opportunity in the market today.

It's the largest white space that we have in digital health over the next decade.

And certainly everybody's chasing AI for discovery, but the real value and the value of the market that hasn't priced yet is this whole idea of how AI runs supply chain, clinical execution, regulatory, quality, and even basic things around operations, how we do medical writing, how do we improve operations with basic AI

All those things are going to be really important to our industry going forward.

And it's really, I would say, in its infancy.

If you look back when we did Preventus in 2010, when we think about monitoring, monitoring was in its infancy in 2010.

If you look today, we can monitor anything.

The devices are small.

There's nothing we can't monitor.

The technology is unbelievable.

That's where AI is today.

We're in the infancy of AI as it relates to the pharma industry and healthcare industry.

It's going to do wonderful things.

I think in some areas we just have to be very careful as it relates to the patient.

We certainly don't want to find out things about the patient we weren't supposed to find out.